Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00426777
Status:
COMPLETED
Last Update Posted:
2012-02-03
First Post:
2007-01-24
Brief Title:
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
Sponsor:
CMX Research
Organization:
CMX Research
Study Overview
Official Title:
A Randomized Single-blind Placebo-controlled Multicentre Study to Evaluate the Effect of Risedronate and Placebo on Bone Mineral Density in Men Undergoing Androgen Deprivation Therapy With Leuprolide Acetate
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prostate cancer patients treated with LHRH agonists eg leuprolide lose bone mineral density This is similar to post-menopausal osteoporosis Risedronate is approved to prevent osteoporosis We hypothesize that risedronate may also be effective in prostate cancer patients treated with LHRH agonists
Detailed Description:
IV bisphosphonates have proven effective in treating bone loss in prostate cancer patients treated with LHRH agonists However it is yet to be determined if an oral bisphosphonate such as risedronate could offer the same benefits
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None